ArticleFrontiers in immunology2025
Identification and validation of CKAP2 as a novel biomarker in the development and progression of rheumatoid arthritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immune cell-specific genetic architecture of Alzheimer's disease revealed by multi-omics analysis for therapeutic target discovery and prioritization.Translational psychiatry · 2026Article
- Integrated Single-Cell Virtual Knockout and Machine Learning Analyses Reveal a Protective Role of CKAP2 in Gastric Cancer.Molecules (Basel, Switzerland) · 2026Article
- Analysis of the differential transcriptome expression profiles during prenatal muscle tissue development in Diqing Tibetan pigs.Frontiers in veterinary science · 2025Article
- Multi-omics-driven biomarker discovery in autoimmune diseases: a comprehensive review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a common chronic joint disease. However, many patients exhibit inadequate responses to treatment due to disease heterogeneity. Identifying novel biomarkers for RA is crucial for advancing molecular diagnosis and identifying potential therapeutic targets. Methods: Synovial tissue transcriptome data from RA patients and healthy controls were obtained from the GEO database. Differentially expressed gene (DEG) analysis, functional enrichment analysis, and weighted gene co-expression network analysis (WGCNA) identified key gene modules in RA. Machine learning algorithms were used to identify hub genes, followed by immune infiltration analysis and gene set variation analysis (GSVA). Mendelian randomization (MR) analysis explored the causal relationship between hub genes and RA. Clinical synovial tissue samples were used to validate CKAP2 expression via quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry (IHC). The potential role of CKAP2 in the pathogenesis of RA was investigated through CCK-8 assay, wound healing assay, transwell migration assay and transwell invasion assay. Results: A total of 242 DEGs were identified between 20 RA patients and 17 healthy controls. Six gene modules were recognized, with the "turquoise" module associated with RA (cor = 0.39, Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.